Case file · May 14, 2025
Rep. Marjorie Taylor Greene bought $TSLA
What Happened Next
$TSLA vs the S&P 500 from the trade date. A buy has an edge when the stock beats the market.
$TSLA · 30 days
−6.4%
S&P 500, same days
+1.6% −8.0 pts edge
$TSLA · 90 days
−2.0%
S&P 500, same days
+9.7% −11.7 pts edge
$TSLA · 180 days
+28.1%
S&P 500, same days
+16.6% +11.4 pts edge
Return
−20%0+20%+40%+60%
The Paper Trail
- $TSLA moved −2.0% in the 90 days after the buy, vs +9.7% for the S&P 500 — a 11.7-point deficit
- Trade date
- May 14, 2025
- Disclosed
- May 20, 2025 (5 days)
- Shuffle Score
- 20/100
- Filing
- Not linked
Marjorie Taylor Greene's History in $TSLA
| Date | Type | Amount | Owner |
|---|---|---|---|
| Sep 3, 2024 | Buy | $1,001 - $15,000 | Not disclosed |
| Oct 21, 2024 | Buy | $1,001 - $15,000 | Not disclosed |
| Nov 1, 2024 | Buy | $1,001 - $15,000 | Not disclosed |
| Nov 7, 2024 | Buy | $1,001 - $15,000 | Not disclosed |
| Jan 8, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| Jan 8, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| Jan 8, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| Jan 8, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| Mar 7, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| Apr 8, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| May 5, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| May 14, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
| Oct 15, 2025 | Buy | $1,001 - $15,000 | Not disclosed |
Who Else Traded $TSLA That Week
Other members of Congress with trades in the same stock within 7 days either side
| Politician | Date | Type | Amount |
|---|---|---|---|
| Jefferson Shreve Rep | May 12, 2025 | Sell | $100,001 - $250,000 |
| Rob Bresnahan Rep | May 12, 2025 | Buy | $1,001 - $15,000 |
| Josh Gottheimer Dem | May 15, 2025 | Buy | $1,001 - $15,000 |
| Josh Gottheimer Dem | May 16, 2025 | Buy | $1,001 - $15,000 |
| Rob Bresnahan Rep | May 16, 2025 | Buy | $1,001 - $15,000 |
Returns use split- and dividend-adjusted closes. Disclosures report ranges, not exact amounts. A well-timed trade is not evidence of wrongdoing. Methodology · Disclaimer